Monsenso A/S
The answer first
Does Monsenso beat the market?
Yes, Monsenso has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 18% of Nordic stocks
- Quality46
- Value16
- Trend39
No. 137 of 195 in healthcare
Max for seven days
Follow Monsenso with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Monsenso
Your first answer is free, no account needed.
Do you own Monsenso, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Monsenso and a few more. Free, no card.
Super Stock+44.6%In short
- Monsenso has risen 31.9% over the past year, including dividends.
- Overall, Monsenso ranks better than 18% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.5%. The price is 99.1% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 18% of Nordic stocks.
No. 137 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 136 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.13
- Asset turnoverSales divided by everything the company owns0.66
- Return on equityProfit divided by equity−100.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 113 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.5
- P/SPrice divided by sales2.4
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 85 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−27.8%
- 6 months−24.2%
- 9 months+35.8%
- 12 months+31.9%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Monsenso
4 funds we follow own Monsenso. The share is how much of the fund the stock makes up.
- Denmark4
From the funds' latest known holdings.
About Monsenso
Monsenso A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 9 employees.
Monsenso A/S develops and sells digital health solution for the treatment of depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, and addiction and substance abuse in Denmark. The company offers Monsenso app for individuals that collects patient-reported and sensor data providing insights into symptoms, adherence, and outcomes.


See the full analysis of Monsenso.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card